PARIS and SAN CARLOS, Calif., May 23, 2019 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced positive results from a study of the company’s Helix™ Biotherapeutic Delivery System for cell therapy used to treat patients early following acute myocardial infarction (AMI) […]
Tag: BioCardia
BioCardia Reports 2019 First Quarter Financial Results and Business Highlights
SAN CARLOS, Calif., May 20, 2019 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the first quarter of 2019 and filed its quarterly report on Form 10-Q for the three months ended March […]
BioCardia Receives FDA Clearance for AVANCE Steerable Introducer for Transseptal Access to Heart
SAN CARLOS, Calif., May 08, 2019 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the AVANCE™ steerable introducer product family, designed for introducing various cardiovascular catheters into the heart, including […]
BioCardia Reports 2018 Financial Results and Recent Business Highlights
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2018, filed its annual 10-K with the Securities and Exchange Commission, and shared recent business highlights. Recent Business […]
BioCardia Submits 510(k) Application to FDA for AVANCE Steerable Introducer for Transseptal Access to Heart
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced its 510(k) submission for U.S. Food and Drug Administration (FDA) clearance of the AVANCE™ steerable introducer, designed for introducing various cardiovascular catheters into the heart, including via the left side […]
Positive 12-Month Data on BioCardia’s Investigational CardiAMP Cell Therapy System for Heart Failure Presented at American Heart Association Scientific Sessions 2018
CHICAGO & SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced positive 12 month data for the roll-in cohort of its pivotal CardiAMP™ Heart Failure Trial studying the investigational CardiAMP Cell Therapy System in adult patients experiencing heart failure following a […]
BioCardia Reports Third Quarter 2018 Financial Results and Business Highlights
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the third quarter 2018 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2018 with the […]
BioCardia Welcomes Cardiovascular Device Veteran Mark Schwartz as Vice President of Clinical Affairs
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia® [OTC: BCDA] today announced that Mark Schwartz, a 25-year veteran of cardiovascular device development, has joined the company as Vice President of Clinical Affairs, effective November 1. Schwartz brings extensive leadership experience in the design and execution of clinical studies for medical devices in the heart […]
BioCardia and CellProThera Partner for Clinical Trial and Marketing in Singapore of Early Stem Cell Therapy for Patients Following Myocardial Infarction
SAN CARLOS, Calif. & MULHOUSE, France–(BUSINESS WIRE)–CellProThera® and BioCardia® [OTC: BCDA] today announced an agreement to expand their current collaboration to the SIngXpand Clinical Trial in Singapore. The study will evaluate the safety and efficacy of in vitro expanded peripheral blood CD34+ stem cells output by the StemXpand® Automated Process and […]
Positive Data On BioCardia’s Investigational CardiAMP Cell Therapy For Heart Failure Presented At Transcatheter Cardiovascular Therapeutics (TCT) Conference
SAN DIEGO and SAN CARLOS, Calif., Sept. 24, 2018 /PRNewswire/ — BioCardia®, Inc. (OTC :BCDA ), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that positive data from two studies of its investigational CardiAMP stem cell therapy were presented today at the Transcatheter Cardiovascular Therapeutics (TCT) conference. CardiAMP cell therapy […]
Recent
ViTAA Medical Secures FDA 510(k) Clearance for AiORTA™ Plan — Marking the First Step in Its Hyper-Precise Aortic Care Platform
HeartBeam Reports Third Quarter 2025 Results
Medtronic Aurora EV-ICD™ system demonstrates exceptional results at six months in the Enlighten real-world post-market study while the OmniaSecure™ defibrillation lead sustains performance at three years in the LEADR Pivotal Trial
Popular
- No commented posts yet